MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Sep 12, 2018 12:00 AM EDT
Morgan Stanley 16th Annual Global Healthcare Conference
Day High:
Day Low:
5:13 AM EDT on Sep 26, 2018

Copyright West LLC. Minimum 15 minutes delayed.